Biogen News Releases and Company Statements

Media Contacts

US Media Relations
Public.Affairs@biogen.com

Europe Media Relations
PublicAffairs.EU@biogen.com

Japan Media Relations
Japan-PA@biogen.com

May 3, 2023
Company Statements

Biogen Files Form 8-K

May 1, 2023
Company Statements

BIOGEN PUBLISHES 2022 ESG REPORT

April 25, 2023
News Release

Biogen Reports First Quarter 2023 Results

January 6, 2023
Company Statements

A statement from Biogen on LEQEMBI™ pricing

October 25, 2022
News Release

Biogen Reports Third Quarter 2022 Results

September 26, 2022
Company Statements

Statement: Biogen Statement On Qui Tam Settlement

July 20, 2022
News Release

Biogen Reports Second Quarter 2022 Results

January 10, 2022
News Release

Biogen to Host Analyst Q&A Call

October 20, 2021
News Release

Biogen Reports Third Quarter 2021 Results

July 22, 2021
News Release

Biogen Reports Second Quarter 2021 Results

June 23, 2021
News Release
Company Statements

Biogen and Eisai Update for the Alzheimer’s Disease Community

June 7, 2021
Company Statements

A Letter from Biogen’s CEO on ADUHELM

April 22, 2021
News Release

Biogen Reports First Quarter 2021 Results

January 13, 2021
Company Statements

A statement about Biogen Political Action Committee

October 21, 2020
News Release

Biogen Reports Q3 2020 Results

September 29, 2020
Company Statements

Statement about the FDA advisory committee on aducanumab

June 2, 2020
Company Statements

Biogen Statement about Director Lynn Schenk

October 22, 2019
News Release

Biogen Reports Q3 2019 Revenues of $3.6 Billion

October 1, 2019
News Release

Biogen Announces Leadership Update

November 26, 2018
News Release

Biogen to Present at the Evercore ISI HealthConX

July 5, 2018
Corporate
Collaborations
News Release
Neurodegenerative Diseases

Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months

March 15, 2018
News Release
Corporate
Neurodegenerative Diseases
Collaborations

Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting

March 12, 2018
News Release
Corporate
Neurodegenerative Diseases
Collaborations

Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia

June 13, 2017
Corporate

Biogen Announces Management Change

June 1, 2017
News Release
Neurodegenerative Diseases
Rare and Genetic Diseases
Collaborations

SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy

April 24, 2017
News Release
Corporate
Neurodegenerative Diseases
Rare and Genetic Diseases
Collaborations

Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy

April 21, 2017
Neurodegenerative Diseases
Rare and Genetic Diseases
Collaborations

Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

April 13, 2017
Corporate
Neurodegenerative Diseases

Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb

January 26, 2017
News Release

Biogen Reports 2016 Revenues of $11.4 Billion

October 8, 2016
News Release
Corporate
Neurodegenerative Diseases
Rare and Genetic Diseases
Collaborations

New Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spinal Muscular Atrophy

September 26, 2016
Neurodegenerative Diseases
Rare and Genetic Diseases
Collaborations

Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy

August 1, 2016
News Release
Corporate
Neurodegenerative Diseases
Rare and Genetic Diseases
Collaborations

Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy

May 16, 2016
News Release
Corporate
Neurodegenerative Diseases
Rare and Genetic Diseases
Collaborations

Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs

April 27, 2016
News Release
Corporate
Neurodegenerative Diseases
Rare and Genetic Diseases

Biogen Appoints Michael Ehlers Executive Vice President, Research and Development

April 14, 2016
Corporate
Rare and Genetic Diseases

Biogen Joins in Celebration of World Hemophilia Day

February 8, 2016
Corporate
Neurodegenerative Diseases
Rare and Genetic Diseases
Collaborations

Biogen Joins Pioneering Target Validation Collaboration

November 11, 2015
Corporate

Steven Holtzman to Retire from Biogen

October 5, 2015
News Release

Biogen Announces Webcast of Investor R&D Day

June 23, 2015
Corporate

Biogen Achieves Carbon Neutrality

May 13, 2015
News Release
Corporate

Biogen Names Matt Griffiths as Chief Information Officer

May 7, 2015
News Release
Corporate

Biogen Announces $5 Billion Share Repurchase Program

March 23, 2015
Corporate

Biogen Idec Becomes Biogen

June 4, 2013
News Release
Corporate

Biogen Idec 2013 Annual Shareholder Meeting Webcast

January 28, 2013
News Release
Corporate

Biogen Idec 2012 Revenue Increases 9% to $5.5 Billion

November 29, 2012
Corporate

Biogen Idec Opens New RTP Facility

November 26, 2012
News Release
Corporate

Biogen Idec to Present at the DB Access BioFEST Conference

October 18, 2012
Neurodegenerative Diseases

Biogen Idec Receives Notification of PDUFA Date Extension

June 5, 2012
News Release
Corporate

Biogen Idec Announces Webcast of 2012 Analyst Day

June 1, 2012
News Release
Corporate

Biogen Idec 2012 Annual Shareholders Meeting Webcast

February 28, 2012
Neurodegenerative Diseases

FDA Approves AVONEX® PEN™ and Dose Titration Regimen

February 14, 2012
News Release
Corporate

Biogen Idec to Acquire Stromedix

January 31, 2012
News Release
Corporate

Biogen Idec Surpasses $5 Billion in 2011 Annual Revenue

November 30, 2011
News Release
Corporate

Biogen Idec to Present at the 2011 Deutsche Bank BioFEST

October 28, 2011
News Release
Corporate

Biogen Idec Reports Third Quarter 2011 Results

October 20, 2011
Neurodegenerative Diseases

Biogen Idec and Elan Receive Notification of PDUFA Date Extension

September 14, 2011
News Release
Corporate

Biogen Idec to Present at the UBS Global Life Sciences Conference

August 31, 2011
Rare and Genetic Diseases

Biogen Idec Announces Webcast of Hemophilia R&D Roundtable

July 26, 2011
News Release
Corporate

Biogen Idec Reports Second Quarter 2011 Results

May 26, 2011
News Release
Corporate

Biogen Idec 2011 Annual Shareholder Meeting Webcast

May 25, 2011
Neurodegenerative Diseases

Biogen Idec Celebrates World MS Day

May 24, 2011
Neurodegenerative Diseases

Biogen Idec Launches Women in MS Educational Initiative

April 21, 2011
News Release
Corporate

Biogen Idec Reports First Quarter 2011 Results

January 21, 2011
Neurodegenerative Diseases

Biogen Idec Receives Negative Opinion from the CHMP on FAMPYRA

January 11, 2011
News Release
Corporate

Biogen Idec Provides Business Update at Investor Meeting

December 9, 2010
News Release
Corporate

Biogen Idec to Present at the 2010 Deutsche Bank BioFEST

October 26, 2010
News Release
Corporate

Biogen Idec Reports Third Quarter 2010 Results

September 21, 2010
Corporate
Rare and Genetic Diseases

Biogen Idec Announces Webcast of Hemophilia R&D Roundtable

July 20, 2010
News Release
Corporate

Biogen Idec Reports Second Quarter 2010 Results

June 30, 2010
News Release
Corporate

Biogen Idec Names George Scangos Chief Executive Officer

June 4, 2010
News Release
Corporate

Biogen Idec 2010 Annual Shareholder Meeting Webcast

May 25, 2010
Neurodegenerative Diseases

Biogen Idec Globally Commemorates Annual World MS Day

February 18, 2010
Rare and Genetic Diseases
Collaborations

Biogen Idec and Swedish Orphan Biovitrum Update Hemophilia Partnership Agreement

February 9, 2010
News Release
Corporate

Biogen Idec Reports Full Year and Fourth Quarter 2009 Results

January 4, 2010
News Release
Corporate

Biogen Idec Names Caroline Dorsa to Board of Directors

December 10, 2009
News Release
Corporate

William D. Young to Become Chairman of Biogen Idec

October 20, 2009
News Release
Corporate

Biogen Idec Reports Third Quarter 2009 Results

September 21, 2009
News Release
Corporate

Biogen Idec Commences Tender Offer for Facet Biotech

September 18, 2009
News Release
Corporate

Biogen Idec to Present at the UBS Global Life Sciences Conference

July 16, 2009
News Release
Corporate

Phillip A. Sharp to Retire from Biogen Idec Board

May 26, 2009
News Release
Corporate

Biogen Idec Sends Letter to Stockholders

May 24, 2009
News Release
Corporate

Biogen Idec Comments on Proxy Advisory Firms’ Reports

April 16, 2009
News Release
Corporate

Biogen Idec Reports First Quarter 2009 Results

April 16, 2009
Neurodegenerative Diseases

Biogen Idec Receives Approval for TYSABRI® High Titer Production

March 30, 2009
News Release
Corporate

Biogen Idec to Present at the 4(th) Annual Citi Biotech Day

March 30, 2009
News Release
Corporate

Biogen Idec Names Robert Hamm Chief Operating Officer

February 6, 2009
News Release
Corporate

Biogen Idec Reports Full Year and Fourth Quarter 2008 Results

February 6, 2009
News Release
Corporate

Biogen Idec Receives Shareholder Proposal

October 21, 2008
News Release
Corporate

Biogen Idec Reports Third Quarter 2008 Results

September 4, 2008
News Release
Corporate

Biogen Idec to Present at the 3rd Annual CITI Biotech Day

July 24, 2008
News Release
Corporate

Biogen Idec Names Brian S. Posner to Board of Directors

July 22, 2008
News Release
Corporate

Biogen Idec Reports Second Quarter 2008 Results

June 19, 2008
News Release
Corporate

Biogen Idec Stockholders Elect Company's Board Nominees

April 23, 2008
News Release
Corporate

Biogen Idec Reports First Quarter 2008 Results

February 29, 2008
News Release
Corporate

Biogen Idec Prices $1.0 Billion Senior Unsecured Notes Offering

February 6, 2008
News Release
Corporate

Biogen Idec Reports Full Year and Fourth Quarter 2007 Results

January 28, 2008
News Release
Corporate

Biogen Idec Receives Director Nomination Proposal

January 7, 2008
News Release
Corporate

Biogen Idec Provides Business Update at Investor Meeting